CCDC25 and hepatocellular carcinoma: In addition, we found that patients with low CCDC25 expression had better sensitivity to Lapatinib, Gefitinib, and Selumetinib, while Ponatinib, Axitinib, Bleomycin, Bosutinib, and Methotrexate may be potentially sensitive drugs for HCC patients with a high expression of CCDC25.